prikaz prve stranice dokumenta Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma
  Download
PDF 1.25 MB
Scientific paper - Original scientific paper
Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma
BioMed Research International, 2014 (2014); 513170. https://doi.org/10.1155/2014/513170
Valković, Toni; Babarović, Emina; Lučin, Ksenija; Štifter, Sanja; Aralica, Merica; Pećanik, Sanja; Seili-Bekafigo, Irena; Duletić-Načinović, Antica; Nemet, Damir; Jonjić, Nives

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Valković, T., Babarović, E., Lučin, K., Štifter, S., Aralica, M., Pećanik, S. ... Jonjić, N. (2014). Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma. BioMed Research International, 2014.. doi: 10.1155/2014/513170

Valković, Toni, et al. "Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma." BioMed Research International, vol. 2014, 2014. https://doi.org/10.1155/2014/513170

Valković, Toni, Emina Babarović, Ksenija Lučin, Sanja Štifter, Merica Aralica, Sanja Pećanik, Irena Seili Bekafigo, Antica Duletić Načinović, Damir Nemet and Nives Jonjić. "Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma." BioMed Research International 2014 (2014). https://doi.org/10.1155/2014/513170

Valković, T., et al. (2014) 'Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma', BioMed Research International, 2014. doi: 10.1155/2014/513170

Valković T, Babarović E, Lučin K, Štifter S, Aralica M, Pećanik S, and sur.. Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma. BioMed Research International [Internet]. 2014 [cited 2024 April 25];2014. doi: 10.1155/2014/513170

T. Valković, et al., "Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma", BioMed Research International, vol. 2014, 2014. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:358750. [Accessed: 25 April 2024]

Metadata
Title (english)Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma
AuthorToni Valković
AuthorEmina Babarović
AuthorKsenija Lučin
AuthorSanja Štifter
AuthorMerica Aralica
AuthorSanja Pećanik
AuthorIrena Seili-Bekafigo
AuthorAntica Duletić-Načinović
AuthorDamir Nemet
AuthorNives Jonjić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of General Pathology and Pathological Anatomy)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Abstract (english)
The aim of this pilot study was to determine the plasma levels of osteopontin (OPN) and vascular endothelial growth factor (VEGF) and find possible association between them and main clinical features and parameters of tumor burden in patient with multiple myeloma (MM). Plasma levels of OPN and VEGF were determined in 44 newly diagnosed MM patients and 24 healthy persons by ELISA method. These values were compared with the presence of anemia, renal dysfunction, and bone lesions as myeloma related clinical manifestations and with serum beta-2 microglobulin and Durie-Salmon clinical stage as prognosticators related to tumor mass. The value of OPN was significantly higher in MM patients with evident bone lesions () and there was also a positive correlation with serum beta-2 microglobulin (; ). Furthermore, patients with lower Durie-Salmon stage had significantly lower OPN and VEGF levels (; , resp.). Our preliminary results found positive association between plasma level of OPN, tumor burden, and bone destruction. Further analysis should provide information about the possible use of OPN as useful clinical biomarker for monitoring bone disease and tumor mass, as well as a prognostic factor, or a possible target for pharmacological intervention.
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleBioMed Research International
Numberingvol. 2014, 513170
p-ISSN2314-6133
e-ISSN2314-6141
DOIhttps://doi.org/10.1155/2014/513170
URN:NBNurn:nbn:hr:184:358750
Publication2014
ProjectNumber: 062-0620095-0079
Title (croatian): Uloga kemokina u patogenezi multiplog mijeloma
Leader: Toni Valković
Jurisdiction: Croatia
Funding stream: ZP
Document URLhttp://dx.doi.org/10.1155/2014/513170
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2017-09-20 21:43:47